The frontiers of genetics and the transformation of medicine and business, R. Field; outpatient prescription drug prices and insurance coverage - an analysis by therapeutic drug class and user characteristics from the 1996 medical expenditure panel survey, G. Edward Miller, J. Moeller; pharmaceutical spending and health outcomes - a state level analysis, P.Y. Cremieux, et al.; too many drugs?, A. Wertheimer, R. Levy, T. O'Connor; factors affecting health services utilization in the medicare population - would providing prescription drug coverage to medicare recipients affect their use of health care resources, M.A. Cifaldi; estimating economic cost of HIV/AIDS-related diseases, I. Farquhar,et al; estimating the social and economic benefits of pharmaceutical innovation - modelling clinical trial results in HIV-disease, K. Simpson, et al; concomitant illness in patients with diabetes - morality, morbidity, benefits of newer treatments, and individual and societal costs, I. Farquhar, et al; factors influencing patient willingness to pay for diabetes - disease state management programmes, J. Barner; assessment of the relationship between quality of life and willingness to pay for in vitro fertilization in patients undergoing treatment for infertility, T. Stavinoha, J. Barner; impact of diabetes on human capital and quality of life, K. Summers, R. Hayes; energy and improved workplace productivity in depression, R. Swindle, K. Kroenke, L. Braun; can mental health treatment be effectively delivered in primary care? a primer for employee benefit design, decision makers, and an outcome research example, R. Swindle, et al; the interaction of depression and smoking on workplace productivity, M. Halpern, Z. Khan, A. Rentz; cost-effectiveness in the prevention of suicide - a population approach, L. von Knorring, et al; payment effects on resource utilization and outcomes for patients with congestive heart failure, E. Kroch, et al.